SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States.

Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.

The company was incorporated in 1995 and is headquartered in New York, New York.